Who is sponsoring NCT05183919?

NCT05183919 is sponsored by Akili Interactive Labs, Inc..

What drugs are being tested in NCT05183919?

Interventions in NCT05183919: Digital Treatment.

What condition does NCT05183919 study?

NCT05183919 studies Attention Deficit Hyperactivity Disorder.

Is NCT05183919 still recruiting?

NCT05183919 is currently completed. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT05183919

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult)

Completed NA Last updated 28 February 2023

What this trial tests

NA trial testing Digital Treatment in Attention Deficit Hyperactivity Disorder in 223 participants. Completed in 13 January 2023.

Timeline

29 November 2021

Primary endpoint
13 January 2023

13 January 2023

Quick facts

Lead sponsor	Akili Interactive Labs, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	223
Start date	29 November 2021
Primary completion	13 January 2023
Estimated completion	13 January 2023
Sites	14 locations across United States

Drugs / interventions tested

Digital Treatment

Conditions studied

Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →

Sponsor

Akili Interactive Labs, Inc.

Who can join

18 and older, any sex, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effects of the videogame-like digital therapy on attentional functioning and symptoms in Adults diagnosed with ADHD.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Digital therapeutics in the clinic.
Phan P, Mitragotri S, Zhao Z. · · 2023 · cited 39× · PMID 37476062 · DOI 10.1002/btm2.10536
Real-time cognitive performance metrics derived from a digital therapeutic for inattention predict ADHD-related clinical outcomes: Replication across three independent trials of AKL-T01.
Stamatis CA, Heusser AC, Simon TJ, Ala'ilima T, et al · · 2024 · cited 4× · PMID 39128918 · DOI 10.1038/s41398-024-03045-0
Two single arm trials of AKL-T01, a digital therapeutic for adolescents and adults with ADHD.
Stamatis CA, Farlow DN, Mercaldi C, Suh M, et al · · 2024 · cited 3× · PMID 38898133 · DOI 10.1038/s44184-024-00075-w
Secondary analyses of sex differences in attention improvements across three clinical trials of a digital therapeutic in children, adolescents, and adults with ADHD.
Flannery JE, Hinshaw SP, Kollins SH, Stamatis CA. · · 2024 · cited 2× · PMID 38685016 · DOI 10.1186/s12889-024-18597-5
ACNP 62nd Annual Meeting: Poster Abstracts P1 – P250
· 2023

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder

Currently open trials in the same condition.

NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting

Other Akili Interactive Labs, Inc. trials

Trials by the same sponsor.

NCT06376032 — EndeavorOTC® Research Study in College Students · NA · active not recruiting
NCT06109051 — EndeavorOTC™ Prospective Product Registry · active not recruiting
NCT05991167 — EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx") · active not recruiting
NCT04897074 — Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents) · NA · completed
NCT03844269 — Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01 · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05183919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Akili Interactive Labs, Inc.
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05183919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing